- Home
- Research
- Mental Health
- Receipt of reproductive safety data among pregnant marijuana users and nonusers.
Most pregnant marijuana users don't receive safety counseling they want
Receipt of reproductive safety data among pregnant marijuana users and nonusers.
AI Summary
A survey of 367 pregnant patients reveals a significant gap in healthcare communication around marijuana use during pregnancy. 23.7% of participants reported using marijuana while pregnant, yet only 25.3% of these users received counseling from their healthcare providers about potential risks. This disparity is particularly striking when compared to the 41.4% of marijuana-using pregnant patients who expressed interest in receiving additional education on the topic. The findings highlight a critical disconnect between patient demand for information and provider delivery of evidence-based counseling.
The research also identified notable demographic patterns in marijuana use among pregnant people. Use was significantly higher among younger patients (33.3% of those aged 18-24), those who had not completed high school, and patients of non-White race/ethnicity (38.9% vs 17.1% among White patients). These disparities suggest that vulnerable populations may face dual challenges: higher rates of marijuana use during pregnancy combined with even lower access to healthcare provider education on reproductive safety.
The gap identified in this study—where only 25% of users received counseling despite 41% wanting more information—underscores an urgent need for improved healthcare infrastructure. Providers need better training and resources to address marijuana use in pregnancy, while patients need accessible, evidence-based information about how cannabis affects both maternal health and fetal development. This research calls for systemic changes to ensure that all pregnant patients have equitable access to critical reproductive safety guidance.
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Review describes AHC and reports cannabidiol as an additional treatment option
Review finds school prevention often covers cannabis, but evidence gaps remain
Antipsychotics eased symptoms, but relapse-prevention evidence remains thin
Explore More Research
Stay informed about the latest cannabis science.